Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

Current guidelines recommend dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitors following percutaneous coronary intervention (PCI). CYP2C19 genotype can guide DAPT selection, prescribing ticagrelor or prasugrel for loss-of-function (LOF) allele carriers (genotype-guided es...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Pharmacogenomics J
Prif Awduron: Limdi, Nita A., Cavallari, Larisa H., Lee, Craig R., Hillegass, William B., Holmes, Ann M., Skaar, Todd C., Pisu, Maria, Dillon, Chrisly, Beitelshees, Amber L., Empey, Philip E., Duarte, Julio D., Diaby, Vakaramoko, Gong, Yan, Johnson, Julie A., Graves, John, Garbett, Shawn, Zhou, Zilu, Peterson, Josh F.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7417282/
https://ncbi.nlm.nih.gov/pubmed/32042096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41397-020-0162-5
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg